We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phytol as an anticarcinogenic and antitumoral agent: An in vivo study in swiss mice with DMBA‐Induced breast cancer.
- Authors
de Alencar, Marcus Vinícius Oliveira Barros; Islam, Muhammad Torequl; de Lima, Rosália Maria Torres; Paz, Márcia Fernanda Correia Jardim; Reis, Antonielly Campinho; Mata, Ana Maria Oliveira Ferreira; Filho, José Williams Gomes de Oliveira; Cerqueira, Gilberto Santos; Ferreira, Paulo Michel Pinheiro; e Sousa, João Marcelo de Castro; Mubarak, Mohammad S.; Melo‐Cavalcante, Ana Amélia de Carvalho
- Abstract
Phytol (PHY) (3,7,11,15‐tetramethylhexadec‐2‐en‐1‐ol) exhibits various pharmacological properties including toxicity and cytotoxicity, and exerts antitumor activity. Owing to the urgent need of new pharmaceutical formulations for breast cancer therapy, this study aimed at the evaluation of antitumor activity of PHY in 7,12‐dimethylbenzanthracene‐cancer‐induced animal model. Comet assay was employed to evaluate the cytogenetics, DNA repair, and antigenotoxic activities of PHY in neoplastic (breast) and non‐neoplastic rodent cells (bone marrow, lymphocytes, and liver). Additionally, hematological, biochemical, histopathological, and immunohistochemical analyses were carried out in experimental animals. Thirty nonpregnant female mice (n = 5) underwent 7 weeks treatment with 6 mg/kg pro‐carcinogen, PHY (4 mg/kg), and cyclophosphamide (25 mg/kg). Induction of cancer was confirmed by histopathology and immunohistochemistry for Ki‐67. Results suggest that PHY exhibits low toxicity in comparison with other groups in hematological, biochemical, histopathological, and organ size parameters. Additionally, PHY showed modulatory effects on the pro‐carcinogen, and induced genotoxicity and apoptosis in breast cancer cells. Furthermore, it showed a DNA damage repair capacity in mouse lymphocytes. These data indicate that PHY may have the potential as an anticancer candidate in pharmaceutical consumption. © 2018 IUBMB Life, 71(1):200–212, 2019
- Subjects
ANTICARCINOGENIC agents; BREAST cancer; ANTINEOPLASTIC agents; LYMPHOCYTES; IMMUNOHISTOCHEMISTRY
- Publication
IUBMB Life, 2019, Vol 71, Issue 2, p200
- ISSN
1521-6543
- Publication type
Article
- DOI
10.1002/iub.1952